Invion Limited (ASX:IVX) Reports Positive Phase I/II Skin Cancer Trial Results
Invion Limited (ASX:IVX) reports positive safety and efficacy results in Phase I/II skin cancer trial, progressing to next study phase.
Category: Healthcare
Noxopharm Limited (ASX:NOX) Receives Approval for HERACLES Clinical Trial
Noxopharm Limited (ASX:NOX) receives ethics approval for its innovative HERACLES clinical trial, advancing new treatments for chronic inflammatory diseases.
Emyria Limited (ASX:EMD) Reports Promising Six-Month PTSD Outcomes and MOU with ANU
Emyria Limited (ASX:EMD) reports promising six-month PTSD treatment outcomes and signs a strategic MOU with ANU to advance mental health research.
Avecho Biotechnology Limited (ASX:AVE) Receives $1.66M R&D Tax Incentive
Avecho Biotechnology Limited (ASX:AVE) receives $1.66M under the R&D Tax Incentive to support its Phase III insomnia trial and commercialization efforts.
Talius Group Limited (ASX:TAL) Announces 10-for-1 Share Consolidation
Talius Group Limited (ASX:TAL) will consolidate its Ordinary Shares on a 10-for-1 basis following shareholder approval, aiming to streamline its capital structure.
HITIQ Ltd (ASX:HIQ) Announces Partnership with AFL Barwon to Expand PROTEQT
A three-year partnership with AFL Barwon aims to expand HITIQ’s PROTEQT concussion management technology to over 25,000 players in regional Victoria.
Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans
Neuren Pharmaceuticals (ASX:NEU) reports a record A$166m income in 2024, driven by DAYBUE sales and initiates Phase 3 trials for NNZ-2591.
Imugene Limited (ASX:IMU) Announces Extraordinary General Meeting
Imugene Limited (ASX:IMU) announces an Extraordinary General Meeting to discuss share consolidation and the issuance of new shares to support its clinical projects.
Recce Pharmaceuticals (ASX:RCE) Secures China Patent for Anti-Infectives
Recce Pharmaceuticals (ASX:RCE) secures a China Patent for its RECCE® anti-infectives, enhancing its global intellectual property portfolio.
OncoSil Medical Limited (ASX:OSL) Announces $8.7M Capital Raise to Drive Commercialisation
OncoSil Medical (ASX:OSL) secures $8.7 million in capital to advance commercialisation and support ongoing clinical trials.